Evidence map›Paper›PMID 41009614›Full record

SynthesisInternational journal of molecular sciences2025

Effects of Rice Bran Supplementation on Metabolic Syndrome-Related Parameters: A Systematic Review and Meta-Analysis.

Sirapatsorn Tantayakhom, Ratchanon Inpan, Kantirat Yaja, Nut Koonrungsesomboon, Supanimit Teekachunhatean, Mingkwan Na Takuathung

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sirapatsorn TantayakhomDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Ratchanon InpanDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0001-7775-3762
Kantirat YajaDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0009-0009-1116-4362
Nut KoonrungsesomboonDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0003-4649-597X
Supanimit TeekachunhateanDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
Mingkwan Na TakuathungDepartment of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0003-4240-5367

Funding

Fundamental Fund 2024, Chiang Mai University FF073/2567
6 · The paper itself

Abstract

Rice bran, a fiber-rich source of bioactive compounds, has gained attention for its potential health benefits, yet its effects on metabolic syndrome (MetS) remain unclear. This study aimed to evaluate the impact of rice bran consumption on anthropometric measures, blood pressure, glycemic control, and lipid profiles in individuals with MetS. A systematic search of PubMed/Medline, Scopus, Cochrane Library, and Embase was conducted up to 30 January 2025, to identify randomized controlled trials (RCTs) assessing rice bran supplementation. Twenty-six RCTs involving 1255 participants (642 in rice bran groups, 613 in controls) were included in the meta-analysis. Weighted mean differences (WMDs) with corresponding

Indexed as

Dietary FiberDietary SupplementsMetabolic SyndromeOryzaBlood PressureHumansLipidsRandomized Controlled Trials as TopicDietary FiberLipidsanthropometric parametersdyslipidemiainsulin resistancemetabolic syndromerice bran

Identifiers

PMID41009614
PMCPMC12469846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.